Skip to main content
. 2018 Jan 12;8:992. doi: 10.3389/fphar.2017.00992

Table 1.

Ferroptosis relevance among various types of cancer.

Cancer type Relevance to ferroptosis Test animals
Breast Combined treatment of siramesine and lapatinib induces ferroptosis by upregulating iron levels (Ma et al., 2016) None
Head and neck Induction of ferroptosis makes cisplatin-resistant cells more sensitive to treatment (Roh et al., 2016); dihydroartemisinin-induced cell death is partially involved in ferroptosis (Lin et al., 2016) Nude mice/none
Acute myeloid leukemia Erastin enhances the sensitivity of AML cells to cytarabine and doxorubicin (Yu et al., 2015) None
Pancreatic ductal adenocarcinoma Artesunate (ART) induces cell death through ferroptosis dependent upon antioxidant homeostasis and increased sensitivity to free intracellular iron (Eling et al., 2015) None
Ovarian The antiproliferative and cytotoxic effects of ART are partially due to ferroptosis (Greenshields et al., 2016) C57BL/6 mice
Hepatocellular carcinoma The cytotoxic effects of sorafenib involves ferroptosis; inhibition of the p62-Keap1-NRF2 pathway increases the anticancer activities of erastin and sorafenib; sorafenib-resistant cells are more sensitive to ferroptosis (Galmiche et al., 2014; Louandre et al., 2015; Sun et al., 2016) Nude mice/C57BL/6 mice
Cervical carcinoma
Osteosarcoma
Prostate adenocarcinoma
HSPB1 is highly inducible following erastin treatment (Sun et al., 2015) NOD/SCID mice
Diffuse large B cell lymphoma Particularly sensitive to ferroptotic cell death; dependent on system Xc- (Yang et al., 2014) None/none
Renal cell carcinomas More sensitive to ferroptosis compared with seven other tissues (Yang et al., 2014)
Non-small cell lung Erastin enhances the effect of cisplatin in NSCLCs (Yamaguchi et al., 2013) Nude mice
Glioblastoma xCT and cystathionine γ-lyase are inducible after temozolomide treatment; erastin enhances sensitivity to temozolomide (Chen et al., 2015; Sehm et al., 2016) None/none
Triple-negative breast Targeting the MUC1-C/xCT pathway could be a therapeutic approach (Hasegawa et al., 2016) None
HHS Vulnerability Disclosure